Clinical observation of Shenshuaining Capsules combined with sevelamer in treatment of hyperphosphatemia in hemodialysis patients
Objective To observe the clinical effect of Shenshuaining Capsules combined with sevelamer in treatment of hyperphosphatemia in hemodialysis patients.Methods A total of 80 hemodialysis patients with hyperphosphatemia treated in Qilu Hospital of Shandong University(Qingdao)from November 2022 to March 2023 were selected and divided into control group and treatment group according to random number table method,with 40 cases in each group.Patients in the control group were po administered with Sevelamer Carbonate Tablets,the initial dose was 1 or 2 tablets at a time,three times daily.Patients in the treatment group were po administered with Shenshuaining Capsules on the basis of the control group,3 grains/time,three times daily.Patients in two groups were treated for 16 weeks.After treatment,the clinical evaluations were evaluated,the levels of blood phosphorus,blood calcium,calcium-phosphorus product,and iPTH in two groups before and after treatment were compared.Results After treatment,the total clinical effective rate of the treatment group was 72.50%,which was significantly higher than that of the control group(47.50%,P<0.05).After treatment,the level of serum phosphorus in the treatment group was continuously decreased,which was significantly lower than that before treatment from the 4th week(P<0.05),and from the 12th week to the control group(P<0.05).After treatment,the level of serum calcium in two groups was significantly lower than that before treatment(P<0.05).After treatment,the level of calcium-phosphorus product in the treatment group continued to decrease as compared with that before treatment(P<0.05).The comparison within the treatment group and between the two groups was consistent with the change trend of blood phosphorus.Conclusion Shenshuanning capsules combined with Sevelam can effectively treat hyperphosphatemia in hemodialysis patients and effectively reduce calcium-phosphorus product without obvious adverse reactions.
NETL
NSTL
万方数据
